Skip to main content
. 2019 Nov;7(21):606. doi: 10.21037/atm.2019.09.20

Table 2. Relationships between FSTL1 expression in the tumor stroma and patient characteristics.

Characteristics Tumor tissue FSTL1 in full scan (n=310), n (%) Tumor tissue FSTL1 in stroma (n=310), n (%)
≤6.5 (n=131) >6.5 (n=179) P ≤3.17 (n=163) >3.17 (n=147) P
Age (years) 0.253 0.057
   ≤59 73 (55.7) 88 (49.2) 93 (57.1) 68 (46.3)
   >59 58 (44.3) 91 (50.8) 70 (42.9) 79 (53.7)
Sex 0.360 0.823
   Female 46 (35.1) 72 (40.2) 63 (38.7) 55 (37.4)
   Male 85 (64.9) 107 (59.8) 100 (61.3) 92 (62.6)
Primary tumor site 0.004 <0.001
   Colon 74 (56.5) 129 (72.1) 122 (74.8) 81 (55.1)
   Rectum 57 (43.5) 50 (27.9) 41 (25.2) 66 (44.9)
Primary tumor size (cm) 0.087 0.975
   ≤4.5 64 (48.9) 105 (58.7) 89 (54.6) 80 (54.4)
   >4.5 67 (51.1) 74 (41.3) 74 (45.4) 67 (45.6)
TNM stage <0.001 0.215
   II 59 (45.0) 42 (23.5) 48 (29.4) 53 (36.1)
   III/IV 72 (55.0) 137 (76.5) 115 (70.6) 94 (63.9)
Histological grade 0.128 0.251
   Well/moderate 105 (80.2) 155 (86.6) 133 (81.6) 127 (86.4)
   Poor 26 (19.8) 24 (13.4) 30 (18.4) 20 (13.6)
CEA level (ng/mL) 0.608 0.647
   ≤5 56 (44.1) 72 (41.1) 65 (41.1) 63 (43.8)
   >5 71 (55.9) 103 (58.9) 93 (58.9) 81 (56.2)
CA19-9 level (U/mL) 0.007 0.116
   ≤35 99 (79.2) 112 (64.7) 105 (66.9) 106 (75.2)
   >35 26 (20.8) 61 (35.3) 52 (33.1) 35 (24.8)

FSTL1, follistatin-like protein 1; CEA, carcinoembryonic antigen before primary tumor resection; CA19-9, cancer antigen 19-9 before primary tumor resection.